


AMINOQUINAZOLINES WHICH INHIBIT SIGNAL TRANSDUCTION
MEDIATED BY TYROSINE KINASES

5 Related Applications

Benefit of U.S. Provisional Application Serial No. 60/230,542, filed on September 5, 2000 is hereby claimed.

Description of the Invention

10 The present invention relates to bicyclic heterocycles of general formula



15 the tautomers, the stereoisomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, especially an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract, and the preparation thereof.

20 In the above general formula I

R_a denotes a hydrogen atom or a methyl group,

R_b denotes a phenyl, benzyl- or 1-phenylethyl group wherein the phenyl nucleus is
25 substituted in each case by the groups R_1 to R_3 , while

R₁ and R₂, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom,

a methyl, ethyl, hydroxy, methoxy, ethoxy, amino, cyano, vinyl or ethynyl group,

5

an aryl, aryloxy, arylmethyl or arylmethoxy group,

a methyl or methoxy group substituted by 1 to 3 fluorine atoms or

10 R₁ together with R₂, if they are bound to adjacent carbon atoms, denote a -CH=CH-CH=CH-, -CH=CH-NH- or -CH=N-NH group and

R₃ denotes a hydrogen, fluorine, chlorine or bromine atom,

15 R_c denotes a hydrogen atom or a methyl group,

X denotes a methyne group substituted by a cyano group or a nitrogen atom,

20 A denotes a 1,1- or 1,2-vinylene group which may be substituted in each case by one or two methyl groups or by a trifluoromethyl group,

an ethynylene group or

a 1,3-butadien-1,4-ylene group optionally substituted by a methyl or trifluoromethyl group,

25

B denotes an alkylene or -CO-alkylene group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms, while the linking of the -CO-alkylene group to the adjacent group A in each case must take place via the carbonyl group,

a -CO-O-alkylene- or -CO-NR₄-alkylene group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms, while the linking to the adjacent group A in each case must take place via the carbonyl group, wherein

5 R₄ denotes a hydrogen atom or a methyl or ethyl group,

or a carbonyl group,

C denotes a 2-oxo-morpholin-4-yl group substituted by the group R₅ or by the group R₅
10 and a C₁₋₄-alkyl group, while

R₅ denotes a C₃₋₄-alkyl, hydroxy-C₁₋₄-alkyl, C₁₋₄-alkoxy-C₁₋₄-alkyl, di-(C₁₋₄-alkyl)-amino-C₁₋₄-alkyl, pyrrolidino-C₁₋₄-alkyl, piperidino-C₁₋₄-alkyl, morpholino-C₁₋₄-alkyl,
4-(C₁₋₄-alkyl)-piperazino-C₁₋₄-alkyl, C₁₋₄-alkylsulphanyl-C₁₋₄-alkyl, C₁₋₄-alkylsulphinyl-
15 C₁₋₄-alkyl, C₁₋₄-alkylsulphonyl-C₁₋₄-alkyl, cyano-C₁₋₄-alkyl, C₁₋₄-alkoxycarbonyl-C₁₋₄-alkyl, aminocarbonyl-C₁₋₄-alkyl, C₁₋₄-alkyl-aminocarbonyl-C₁₋₄-alkyl, di-(C₁₋₄-alkyl)aminocarbonyl-C₁₋₄-alkyl, pyrrolidinocarbonyl-C₁₋₄-alkyl, piperidinocarbonyl-C₁₋₄-alkyl, morpholinocarbonyl-C₁₋₄-alkyl or a 4-(C₁₋₄-alkyl)-piperazino-carbonyl-C₁₋₄-alkyl group,

20 a 2-oxo-morpholin-4-yl group substituted by two groups R₅, where R₅ is as hereinbefore defined and the two groups R₅ may be identical or different,

a 2-oxo-morpholin-4-yl group, wherein the two hydrogen atoms of a methylene group are
25 replaced by a -(CH₂)_m, -CH₂-Y-CH₂, -CH₂-Y-CH₂-CH₂, -CH₂CH₂-Y-CH₂CH₂- or -CH₂CH₂-Y-CH₂CH₂CH₂- bridge optionally substituted by one or two C₁₋₂-alkyl groups, while

m denotes the number 2, 3, 4, 5 or 6 and

30 Y denotes an oxygen or sulphur atom, a sulphinyl, sulphonyl or C₁₋₄-alkylimino group,

a 2-oxo-morpholin-4-yl group, wherein a hydrogen atom in the 5 position together with a hydrogen atom in the 6 position is replaced by a $-(CH_2)_n$, $-CH_2-Y-CH_2$, $-CH_2-Y-CH_2CH_2-$ or $-CH_2CH_2-Y-CH_2$ -bridge, while

- 5 Y is as hereinbefore defined and
n denotes the number 2, 3 or 4,

or, if D together with E denotes a group R_d , it may also denote a 2-oxo-morpholin-4-yl group which may be substituted by 1 to 4 C_{1-2} -alkyl groups,

10

D denotes a $-O-C_{1-6}$ -alkylene group, while the alkylene moiety is linked to the group E, or an oxygen atom, while this may not be linked to a nitrogen atom of the group E, and

- 15 E denotes an amino group substituted by 2 C_{1-4} -alkyl groups, wherein the alkyl groups may be identical or different and each alkyl moiety may be substituted from the 2 position by a C_{1-4} -alkoxy or di- $(C_{1-4}$ -alkyl)-amino group or by a 4- to 7-membered alkyleneimino group, while in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group may be replaced in the 4 position by an oxygen or sulphur atom or by a
20 sulphinyl, sulphonyl- or N- $(C_{1-4}$ -alkyl)-imino group,

a 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 methyl groups,

- a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups,
25 wherein in each case a methylene group in the 4 position is replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl- or N- $(C_{1-4}$ -alkyl)-imino group,

an imidazolyl group optionally substituted by 1 to 3 methyl groups,

- 30 a C_{5-7} -cycloalkyl group, wherein a methylene group is replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl or N- $(C_{1-4}$ -alkyl)-imino group, or

D together with E denotes a hydrogen atom,

5 a C₁₋₆-alkoxy group optionally substituted from the 2 position by a hydroxy- or C₁₋₄-alkoxy group,

a C₃₋₇-cycloalkoxy- or C₃₋₇-cycloalkyl-C₁₋₄-alkoxy group,

10 or a group R_d, where

R_d denotes a C₂₋₆-alkoxy group which is substituted from the 2 position by a C₄₋₇-cycloalkoxy- or C₃₋₇-cycloalkyl-C₁₋₃-alkoxy group,

15 a C₄₋₇-cycloalkoxy- or C₃₋₇-cycloalkyl-C₁₋₆-alkoxy group wherein the cycloalkyl moiety in each case is substituted by a C₁₋₄-alkyl, C₁₋₄-alkoxy, di-(C₁₋₄-alkyl)-amino, pyrrolidino, piperidino, morpholino, piperazino, 4-(C₁₋₂-alkyl)-piperazino, C₁₋₄-alkoxy-C₁₋₂-alkyl, di-(C₁₋₄-alkyl)-amino-C₁₋₂-alkyl, pyrrolidino-C₁₋₂-alkyl, piperidino-C₁₋₂-alkyl, morpholino-C₁₋₂-alkyl, piperazino-C₁₋₂-alkyl- or 4-(C₁₋₂-alkyl)-piperazino-C₁₋₂-alkyl group, while the abovementioned cycloalkyl moieties may additionally be substituted by a methyl or ethyl group,

20

while, unless otherwise stated, by the aryl moieties mentioned in the definition of the abovementioned groups is meant a phenyl group which may be mono- or disubstituted by R₆, while the substituents may be identical or different and

25

R₆ denotes a fluorine, chlorine, bromine or iodine atom, a C₁₋₂-alkyl, trifluoromethyl or C₁₋₂-alkoxy group, or

30 two groups R₆, if they are bound to adjacent carbon atoms, together represent a C₃₋₄-alkylene, methylenedioxy or 1,3-butadien-1,4-ylene group.

Preferred compounds of the above general formula I are those wherein

R_a denotes a hydrogen atom,

- 5 R_b denotes a benzyl or 1-phenylethyl group or a phenyl group substituted by the groups R₁ and R₂, while

R₁ denotes a hydrogen, fluorine, chlorine or bromine atom, a methyl, trifluoromethyl, cyano or ethynyl group and

- 10 R₂ denotes a hydrogen or fluorine atom,

R_c denotes a hydrogen atom,

X denotes a nitrogen atom,

- 15

A denotes a 1,2-vinylene group,

B denotes a C₁₋₄-alkylene group,

- 20 C denotes a 2-oxo-morpholin-4-yl group substituted by the group R₅ or by the group R₅ and a C₁₋₄-alkyl group, while

- R₅ denotes a C₃₋₄-alkyl, C₁₋₂-alkoxy-C₁₋₄-alkyl, di-(C₁₋₂-alkyl)-amino-C₁₋₄-alkyl, pyrrolidino-C₁₋₄-alkyl, piperidino-C₁₋₄-alkyl, morpholino-C₁₋₄-alkyl, 4-(C₁₋₂-alkyl)-
25 piperazino-C₁₋₄-alkyl, C₁₋₂-alkylsulphanyl-C₁₋₄-alkyl, C₁₋₂-alkylsulphinyl-C₁₋₄-alkyl, C₁₋₂-alkylsulphonyl-C₁₋₄-alkyl, cyano-C₁₋₄-alkyl, C₁₋₂-alkoxycarbonyl-C₁₋₄-alkyl, aminocarbonyl-C₁₋₄-alkyl, C₁₋₂-alkyl-aminocarbonyl-C₁₋₄-alkyl, di-(C₁₋₂-alkyl)-aminocarbonyl-C₁₋₄-alkyl, pyrrolidinocarbonyl-C₁₋₄-alkyl, piperidinocarbonyl-C₁₋₄-alkyl, morpholinocarbonyl-C₁₋₄-alkyl- or a 4-(C₁₋₂-alkyl)-piperazinocarbonyl-C₁₋₄-alkyl group,

- 30

a 2-oxo-morpholin-4-yl group substituted by two groups R_5 , while R_5 is as hereinbefore defined and the two groups R_5 may be identical or different,

5 a 2-oxo-morpholin-4-yl group, wherein the two hydrogen atoms of a methylene group are replaced by a $-(CH_2)_m$, $-CH_2-Y-CH_2$, $-CH_2-Y-CH_2-CH_2-$ or $-CH_2CH_2-Y-CH_2CH_2$ -bridge, while

m denotes the number 2, 3, 4 or 5 and

Y denotes an oxygen or sulphur atom, a sulphinyl, sulphonyl or C_{1-2} -alkylimino group,

10

a 2-oxo-morpholin-4-yl group, wherein a hydrogen atom in the 5 position together with a hydrogen atom in the 6 position is replaced by a $-(CH_2)_n$, $-CH_2-Y-CH_2$, $-CH_2-Y-CH_2CH_2-$ or $-CH_2CH_2-Y-CH_2$ -bridge, where

15 Y is as hereinbefore defined and

n denotes the number 2, 3 or 4,

or, if D together with E denotes a group R_d , it may also denote a 2-oxo-morpholin-4-yl group which may be substituted by 1 or 2 methyl or ethyl groups,

20

D denotes a $-O-C_{1-4}$ -alkylene group, while the alkylene moiety is linked to the group E , and

25 E denotes a dimethylamino, diethylamino, pyrrolidino, piperidino, morpholino, 4-methyl-piperazino- or 4-ethyl-piperazino group or

D together with E denotes a hydrogen atom,

30 a methoxy, ethoxy, 2-methoxy-ethoxy, 3-methoxy-propyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranylmethoxy or tetrahydropyranylmethoxy group,



a cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy or cyclohexylmethoxy group or

5 a group R_d , where

R_d denotes a 2-(cyclobutyloxy)-ethoxy, 2-(cyclopentyloxy)-ethoxy, 2-(cyclopropylmethoxy)-ethoxy or 2-(cyclobutylmethoxy)-ethoxy group,

10 the tautomers, stereoisomers and salts thereof.

Particularly preferred compounds of the above general formula I are those wherein

R_a denotes a hydrogen atom,

15

R_b denotes a 1-phenylethyl, 3-methylphenyl, 3-chlorophenyl, 3-bromophenyl- or 3-chloro-4-fluorophenyl group,

R_c denotes a hydrogen atom,

20

X denotes a nitrogen atom,

A denotes a 1,2-vinylene group,

25 B denotes a methylene group,

C denotes a 2-oxo-morpholin-4-yl group which is substituted by a methoxymethyl, methoxyethyl, ethoxymethyl, ethoxyethyl, dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl, diethylaminoethyl, cyanomethyl or cyanoethyl group,

30

- a 2-oxo-morpholin-4-yl group, wherein the two hydrogen atoms of a methylene group are replaced by a -CH₂CH₂, -CH₂CH₂CH₂, -CH₂CH₂CH₂CH₂, -CH₂CH₂CH₂CH₂CH₂, -CH₂-O-CH₂CH₂, -CH₂-NCH₃-CH₂CH₂, -CH₂-NC₂H₅-CH₂CH₂, -CH₂CH₂-O-CH₂CH₂, -CH₂CH₂-NCH₃-CH₂CH₂- or -CH₂CH₂-NC₂H₅-CH₂CH₂- bridge,
- 5 a 2-oxo-morpholin-4-yl group, wherein a hydrogen atom in the 5 position together with a hydrogen atom in the 6 position is replaced by a -CH₂CH₂CH₂, -CH₂CH₂CH₂CH₂, -CH₂-O-CH₂, -CH₂-NCH₃-CH₂, -CH₂-NC₂H₅-CH₂, -CH₂-O-CH₂CH₂, -CH₂-NCH₃-CH₂CH₂, -CH₂-NC₂H₅-CH₂CH₂, -CH₂CH₂-O-CH₂, -CH₂CH₂-NCH₃-CH₂- or
- 10 -CH₂CH₂-NC₂H₅-CH₂- bridge,
- or, if D together with E denotes a group R_d, it may also denote a 2-oxo-morpholin-4-yl group which is substituted by 1 or 2 methyl groups, and
- 15 D together with E denotes a hydrogen atom,
- a methoxy, ethoxy, 2-methoxy-ethoxy, 3-methoxy-propyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuranylmethoxy group,
- 20 a cyclobutyloxy, cyclopentyloxy, cyclopropylmethoxy, cyclobutylmethoxy or cyclopentylmethoxy group or
- a group R_d, where
- 25 R_d denotes a 2-(cyclobutyloxy)-ethoxy, 2-(cyclopentyloxy)-ethoxy, 2-(cyclopropylmethoxy)-ethoxy or 2-(cyclobutylmethoxy)-ethoxy group,
- the tautomers, stereoisomers and salts thereof.
- 30 Most particularly preferred compounds of the above general formula I are those wherein

R_a denotes a hydrogen atom,

R_b denotes a 3-chloro-4-fluorophenyl group,

5 R_c denotes a hydrogen atom,

X denotes a nitrogen atom,

A denotes a 1,2-vinylene group,

10

B denotes a methylene group,

C denotes a 2-oxo-morpholin-4-yl group which is substituted by a methoxymethyl or methoxyethyl group, or

15

a 2-oxo-morpholin-4-yl group, wherein the two hydrogen atoms of a methylene group are replaced by a -CH₂CH₂-O-CH₂CH₂- bridge, and

D together with E denotes a hydrogen atom, a methoxy or cyclopropylmethoxy group,

20

the tautomers, stereoisomers and salts thereof.

The following particularly preferred compounds of the above general formula I are mentioned by way of example:

25

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{{4-((*R*)-2-methoxymethyl-6-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline,

(2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{{4-(2-oxo-1,9-dioxo-4-aza-spiro[5.5]undec-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline and

30

(3) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-({4-[2-(2-methoxy-ethyl)-6-oxo-morpholin-4-yl]-1-oxo-2-buten-1-yl} amino)-7-cyclopropylmethoxy-quinazoline,


the tautomers, stereoisomers and salts thereof.

5

The compounds of general formula I may be prepared, for example, by the following methods:

reacting a compound of general formula

10



optionally formed in a reaction mixture,

wherein

15

R_a to R_c , A, B, D, E and X are as hereinbefore defined and

Z_1 denotes a leaving group such as a halogen atom, e.g. a chlorine or bromine atom, or a hydroxy group,

with a compound of general formula

20

H - C , (III)

wherein

C is as hereinbefore defined.

25

The reaction is optionally carried out in a solvent or mixture of solvents such as acetonitrile, methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene,

5

10

20

25

-12-

wherein

R_a to R_c, A, B, D, E and X are as hereinbefore defined and

C' denotes a correspondingly substituted N-(carboxymethyl)-N-(2-hydroxyethyl)-amino or N-(C₁₋₄-alkyloxycarbonylmethyl)-N-(2-hydroxyethyl)-amino group which can be converted
5 into a C group by cyclisation.

The reaction is optionally carried out in a solvent or mixture of solvents such as methylene chloride, acetonitrile, dimethylformamide, dimethylsulphoxide, sulpholane, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane, expediently in
10 the presence of an anhydrous acid such as trifluoroacetic acid, methanesulphonic acid or sulphuric acid or in the presence of a dehydrating agent, e.g. in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexyl carbodiimide, N,N'-dicyclohexyl carbodiimide/N-hydroxysuccinimide or 1-hydroxy-benzotriazole,
15 N,N'-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, at temperatures between -20 and 200°C, but preferably at temperatures between -10 and 160°C.

In the reactions described hereinbefore, any reactive groups present such as hydroxy, carboxy or imino groups may be protected during the reaction by conventional protecting
20 groups which are cleaved again after the reaction.

For example, a protecting group for a hydroxy group may be a trimethylsilyl, acetyl, benzoyl, methyl, ethyl, tert.butyl, trityl, benzyl or tetrahydropyranyl group,

25 a protecting group for a carboxyl group may be a trimethylsilyl, methyl, ethyl, tert.butyl, benzyl or tetrahydropyranyl group and

protecting groups for an imino group may be a formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert.butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-
30 diethoxybenzyl group.

Any protecting group used is optionally subsequently cleaved for example by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as sodium hydroxide or potassium hydroxide or aprotically, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120°C, preferably at temperatures between 10 and 100°C.

However, a benzyl, methoxybenzyl or benzyloxycarbonyl group is cleaved, for example, hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100°C, but preferably at ambient temperatures between 20 and 60°C, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar. A 2,4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisole.

A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid or by treating with iodotrimethylsilane, optionally using a solvent such as methylene chloride, dioxane, methanol or diethylether.

A trifluoroacetyl group is preferably cleaved by treating with an acid such as hydrochloric acid, optionally in the presence of a solvent such as acetic acid at temperatures between 50 and 120°C or by treating with sodium hydroxide solution, optionally in the presence of a solvent such as tetrahydrofuran at temperatures between 0 and 50°C.

Moreover, the compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers, as mentioned hereinbefore. Thus, for example, cis/trans mixtures may be resolved into their cis and trans isomers, and compounds with at least one optically active carbon atom may be separated into their enantiomers.

Thus, for example, the cis/trans mixtures may be resolved by chromatography into the cis and trans isomers thereof, the compounds of general formula I obtained which occur as racemates may be separated by methods known *per se* (cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical antipodes and compounds of general formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known *per se*, e.g. by chromatography and/or fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.

The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-o-tolytartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+) or (-)-menthol and an optically active acyl group in amides, for example, may be a (+)-or (-)-menthyloxycarbonyl.

Furthermore, the compounds of formula I may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.

The compounds of general formulae II to IV used as starting materials are known from the literature in some cases or may be obtained by methods known from the literature (see Examples I to VII).

- 5 As already mentioned hereinbefore, the compounds of general formula I according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by the Epidermal Growth Factor receptor (EGF-R), whilst this may be achieved for example by inhibiting ligand bonding, receptor dimerisation or tyrosine kinase itself. It is also possible
10 that the transmission of signals to components located further down is blocked.

The biological properties of the new compounds were investigated as follows:

- 15 The inhibition of EGF-R-mediated signal transmission can be demonstrated e.g. with cells which express human EGF-R and whose survival and proliferation depend on stimulation by EGF or TGF-alpha. A cell line of murine origin dependent on interleukin-3-(IL-3) which was genetically modified to express functional human EGF-R was used here. The proliferation of these cells known as F/L-HERc can therefore be stimulated either by murine IL-3 or by EGF (cf. von Rüden, T. et al. in EMBO J. 7, 2749-2756 (1988) and
20 Pierce, J. H. et al. in Science 239, 628-631 (1988)).

- The starting material used for the F/L-HERc cells was the cell line FDC-P₁, the production of which has been described by Dexter, T. M. et al. in J. Exp. Med. 152, 1036-1047 (1980). Alternatively, however, other growth-factor-dependent cells may also be used (cf. for
25 example Pierce, J. H. et al. in Science 239, 628-631 (1988), Shibuya, H. et al. in Cell 70, 57-67 (1992) and Alexander, W. S. et al. in EMBO J. 10, 3683-3691 (1991)). For expressing the human EGF-R cDNA (cf. Ullrich, A. et al. in Nature 309, 418-425 (1984)) recombinant retroviruses were used as described by von Rüden, T. et al., EMBO J. 7, 2749-2756 (1988), except that the retroviral vector LXS_N (cf. Miller, A. D. et al. in
30 BioTechniques 7, 980-990 (1989)) was used for the expression of the EGF-R cDNA and

the line GP+E86 (cf. Markowitz, D. et al. in J. Virol. 62, 1120-1124 (1988)) was used as the packaging cell.

The test was performed as follows:

5

F/L-HERc cells were cultivated in RPMI/1640 medium (BioWhittaker), supplemented with 10 % foetal calf serum (FCS, Boehringer Mannheim), 2 mM glutamine (BioWhittaker), standard antibiotics and 20 ng/ml of human EGF (Promega), at 37°C and 5% CO₂. In order to investigate the inhibitory activity of the compounds according to the invention, 1.5 x 10⁴ cells per well were cultivated in triplicate in 96-well dishes in the above medium (200 µl), the cell proliferation being stimulated with either EGF (20 ng/ml) or murine IL-3. The IL-3 used was obtained from culture supernatants of the cell line X63/0 mIL-3 (cf. Karasuyama, H. et al. in Eur. J. Immunol. 18, 97-104 (1988)). The compounds according to the invention were dissolved in 100% dimethylsulphoxide (DMSO) and added to the cultures in various dilutions, the maximum DMSO concentration being 1%. The cultures were incubated for 48 hours at 37°C.

15

In order to determine the inhibitory activity of the compounds according to the invention the relative cell number was measured in O.D. units using the Cell Titer 96™ Aqueous Non-Radioactive Cell Proliferation Assay (Promega). The relative cell number was calculated as a percentage of the control (F/LHERc cells without inhibitor) and the concentration of active substance which inhibits the proliferation of the cells by 50% (IC₅₀) was derived therefrom. The following results were obtained:

20

Compound (Example No.)	Inhibition of the EGF-dependent proliferation IC ₅₀ [nM]
1	2

25

The compounds of general formula I according to the invention thus inhibit the signal transduction by tyrosine kinases, as demonstrated by the example of the human EGF

receptor, and are therefore useful for treating pathophysiological processes caused by hyperfunction of tyrosine kinases. These are e.g. benign or malignant tumours, particularly tumours of epithelial and neuroepithelial origin, metastatisation and the abnormal proliferation of vascular endothelial cells (neoangiogenesis).

5

The compounds according to the invention are also useful for preventing and treating diseases of the airways and lungs which are accompanied by increased or altered production of mucus caused by stimulation of tyrosine kinases, e.g. in inflammatory diseases of the airways such as chronic bronchitis, chronic obstructive bronchitis, asthma, bronchiectasias, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, α 1-antitrypsin deficiency, or coughs, pulmonary emphysema, pulmonary fibrosis and hyperreactive airways.

The compounds are also suitable for treating diseases of the gastrointestinal tract and bile duct and gall bladder which are associated with disrupted activity of the tyrosine kinases, such as may be found e.g. in chronic inflammatory changes such as cholecystitis, Crohn's disease, ulcerative colitis, and ulcers in the gastrointestinal tract or such as may occur in diseases of the gastrointestinal tract which are associated with increased secretions, such as Ménétrier's disease, secreting adenomas and protein loss syndrome,

20

also for treating nasal polyps and polyps of the gastrointestinal tract of various origins, such as for example villous or adenomatous polyps of the large bowel, but also polyps in familial polyposis coli, intestinal polyps in Gardner's syndrome, polyps throughout the entire gastrointestinal tract in Peutz-Jeghers Syndrome, inflammatory pseudopolyps, juvenile polyps, colitis cystica profunda and pneumatosis cystoides intestinales.

25

Moreover, the compounds of general formula I and the physiologically acceptable salts thereof may be used to treat kidney diseases, particularly cystic changes as in cystic kidneys, for treating renal cysts which may be idiopathic in origin or which occur in syndromes such as e.g. tubercular sclerosis, in von-Hippel-Lindau Syndrome, in nephronophthisis and spongy kidney and other diseases caused by abnormal functioning of

30

tyrosine kinases such as e.g. epidermal hyperproliferation (psoriasis), inflammatory processes, diseases of the immune system, hyperproliferation of haematopoietic cells, etc.

By reason of their biological properties the compounds according to the invention may be
5 used on their own or in conjunction with other pharmacologically active compounds, for example in tumour therapy, in monotherapy or in conjunction with other anti-tumour therapeutic agents, for example in combination with topoisomerase inhibitors (e.g. etoposide), mitosis inhibitors (e.g. vinblastine), compounds which interact with nucleic acids (e.g. cis-platin, cyclophosphamide, adriamycin), hormone antagonists (e.g.
10 tamoxifen), inhibitors of metabolic processes (e.g. 5-FU etc.), cytokines (e.g. interferons), antibodies, etc. For treating respiratory tract diseases, these compounds may be used on their own or in conjunction with other therapeutic agents for the airways, such as substances with a secretolytic, broncholytic and/or anti-inflammatory activity. For treating diseases in the region of the gastrointestinal tract, these compounds may also be
15 administered on their own or in conjunction with substances having an effect on motility or secretion or with anti-inflammatory substances. These combinations may be administered either simultaneously or sequentially.

These compounds may be administered either on their own or in conjunction with other
20 active substances by intravenous, subcutaneous, intramuscular, intrarectal, intraperitoneal or intranasal route, by inhalation or transdermally or orally, whilst aerosol formulations are particularly suitable for inhalation.

For pharmaceutical use the compounds according to the invention are generally used for
25 warm-blooded vertebrates, particularly humans, in doses of 0.01-100 mg/kg of body weight, preferably 0.1-15 mg/kg. For administration they are formulated with one or more conventional inert carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol,
30 propylene glycol, stearyl alcohol, carboxymethylcellulose or fatty substances such as hard

fat or suitable mixtures thereof in conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions, solutions, sprays or suppositories.

The following Examples are intended to illustrate the present invention without restricting
5 it:

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223

Preparation of the starting products:

Example I

- 5 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(4-{N-[(ethoxy-carbonyl)methyl]-N-((*R*)-2-hydroxy-3-methoxy-propyl)-amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline

1.34 ml of oxalyl chloride are pipetted into 1.29 g of bromocrotonic acid in 30 ml of methylene chloride, then another 65 µl of N,N-dimethylformamide are added. The reaction mixture is stirred for about 45 minutes at ambient temperature until the development of gas has ceased, and then evaporated to dryness. The crude bromocrotonic acid chloride is taken up in 15 ml of methylene chloride and, while being cooled in an ice bath, added dropwise within five minutes to a solution of 2.00 g of 6-amino-4-[(3-chloro-4-fluoro-phenyl)amino]-7-cyclopropylmethoxy-quinazoline and 2.91 ml of diisopropylethylamine in 60 ml of tetrahydrofuran. The reaction mixture is stirred for 45 minutes while cooling with an ice bath, then stirred for two hours at ambient temperature. Then a solution of 1.80 g of ethyl ((*R*)-2-hydroxy-3-methoxy-propylamino)-acetate in 5 ml of tetrahydrofuran is added. The reaction mixture is heated to 60°C for about 40 hours. To work it up, the reaction mixture is evaporated down. The flask residue is dissolved in 200 ml of ethyl acetate, washed with 5% citric acid solution and saturated sodium chloride solution and evaporated down to about 100 ml. The concentrate is chromatographed through a silica gel column using ethyl acetate/methanol (100:0 to 70:30) as eluant. The title compound is obtained, contaminated with some already cyclised product, as a brownish foam.

Yield: 1.10 g (32 % of theory),

- 25 R_f value: 0.42 (silica gel, methylene chloride/methanol = 9:1)

Mass spectrum (ESI): m/z = 614, 616 $[M-H]^-$

The following compound is obtained analogously to Example I:

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(4-{N-[(4-hydroxy-tetrahydropyran-4-yl)methyl]-N-[(ethoxycarbonyl)methyl]-amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline

R_f value: 0.40 (silica gel, methylene chloride/methanol = 9:1)

Mass spectrum (ESI⁻): m/z = 640, 642 [M-H]⁻

(2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(4-{N-[(ethoxycarbonyl)methyl]-N-((S)-2-hydroxy-3-methoxy-propyl)-amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline

R_f value: 0.30 (silica gel, methylene chloride/methanol = 20:1)

Mass spectrum (ESI⁺): m/z = 616, 618 [M+H]⁺

15 Example II

6-amino-4-[(3-chloro-4-fluoro-phenyl)amino]-7-cyclopropyl-methoxy-quinazoline

36.02 g of 4-[(3-chloro-4-fluoro-phenyl)amino]-7-cyclopropylmethoxy-6-nitro-quinazoline are suspended in a mixture of 1080 ml of ethanol, 144 ml of glacial acetic acid and 360 ml of water and refluxed, whereupon the substance goes into solution. 20.70 g of iron powder are then cautiously added batchwise. After 30 minutes the reaction is complete and the reaction mixture is evaporated to dryness. The residue is taken up in 1200 ml of methylene chloride/methanol (9:1) and made alkaline with 33% ammonia solution. The iron slurry is suction filtered through a high-speed filter and washed with 500 ml of methylene chloride/methanol (9:1). The brown filtrate is filtered through a silica gel package, washed with a total of 2000 ml of methylene chloride/methanol (9:1) and evaporated down. The flask residue is suspended with 140 ml of diethylether, suction filtered and dried in the air.

Yield: 29.70 g (89 % of theory),

30 Melting point: 208°C

Mass spectrum (ESI⁺): m/z = 359, 361 [M+H]⁺

Example III4-[(3-chloro-4-fluoro-phenyl)amino]-7-cyclopropylmethoxy-6-nitro-quinazoline

- 5 29.36 g of cyclopropylmethanol are dissolved in 310 ml of N,N-dimethylformamide and cooled to about 10°C in an ice bath. Then 41.58 g of potassium tert. butoxide are added batchwise, while the temperature should remain below 15°C. The reaction mixture is then stirred for another 30 minutes at 10°C, after which time 31.19 g of 4-[(3-chloro-4-fluoro-phenyl)amino]-7-fluoro-6-nitro-quinazoline are added batchwise, while again the
- 10 temperature should not exceed 15°C. The deep red reaction mixture is stirred for another hour at 15°C. For working up, the mixture is poured onto 2.5 l of water and neutralised with 2N hydrochloric acid. The yellowish precipitate formed is suction filtered, washed with water and dried at 50°C in a drying cupboard.

Yield: 36.02 g (100 % of theory),

- 15 Melting point: 204°C

Mass spectrum (ESI⁺): m/z = 389, 391 [M+H]⁺

Example IV

- 20 Ethyl ((R)-2-hydroxy-3-methoxy-propylamino)-acetate

- The crude product solution of ethyl [N-benzyl-N-((R)-2-hydroxy-3-methoxy-prop-1-yl)-amino]-acetate in ethanol obtained in Example V is combined with another 20 ml of absolute ethanol and hydrogenated in the presence of 500 mg of palladium (10% on activated charcoal) as catalyst for about another four hours at ambient temperature until the
- 25 calculated amount of hydrogen has been absorbed. For working up, the catalyst is filtered off and the filtrate is evaporated down *in vacuo*, leaving a colourless viscous oil.

Yield: 1.90 g (88 % of theory),

R_f value: 0.48 (silica gel, methylene chloride/methanol = 9:1)

Mass spectrum (ESI⁺): m/z = 192 [M+H]⁺

- 30

The following compounds are obtained analogously to Example IV:

(1) (2-hydroxy-4-methoxy-butylamino)-acetic acid

(The hydrogenation is carried out in a mixture of methanol/water = 10:1.)

R_f value: 0.80 (Reversed phase ready-made TLC plate (E. Merck),

5 acetonitrile/water/trifluoroacetic acid = 50:50:1)

Mass spectrum (ESI): m/z = 176 [M-H]⁻

(2) ethyl ((S)-2-Hydroxy-3-methoxy-propylamino)-acetate

Mass spectrum (EI): m/z = 191 [M]⁺

10

Example V

Ethyl [N-benzyl-N-((R)-2-hydroxy-3-methoxy-propyl)-amino]-acetate

A mixture of 2.20 g of ethyl N-benzylamino-acetate and 1.00 g of (R)(-)-2-

15 (methoxymethyl)-oxirane (Fluka) in 10 ml of absolute ethanol is left to stand over a weekend under an argon atmosphere. The crude product solution obtained is further reacted without any more purification.

R_f value: 0.57 (silica gel, cyclohexane/ethyl acetate = 1:1)

Mass spectrum (ESI⁺): m/z = 282 [M+H]⁺

20

The following compounds are obtained analogously to Example V:

(1) [N-benzyl-N-(2-hydroxy-4-methoxy-butyl)-amino]-acetic acid

(the reaction is carried out with N-benzylglycine in 1N sodium hydroxide solution.)

25 R_f value: 0.57 (Reversed phase ready-made TLC plate (E. Merck),
acetonitrile/water/trifluoroacetic acid = 50:50:1)

Mass spectrum (ESI): m/z = 266 [M-H]⁻

(2) ethyl [N-benzyl-N-((S)-2-hydroxy-3-methoxy-propyl)-amino]-acetate

30 R_f value: 0.57 (silica gel, cyclohexane/ethyl acetate = 1:1)

Mass spectrum (ESI⁺): m/z = 282 [M+H]⁺

Example VI

Ethyl(4-hydroxy-tetrahydropyran-4-yl)methylamino]-acetate

- 5 5.30 g of glycine ethyl ester hydrochloride are dissolved in 10 ml of saturated potassium carbonate solution. Then 10 g of solid potassium carbonate are added while cooling with an ice bath. The mass formed is extracted thoroughly several times with diethylether. The combined ether extracts are dried over sodium sulphate and evaporated down. The glycine ethyl ester is dissolved together with 4.20 g 1,6-dioxaspiro[2.5]octane in 20 ml of absolute ethanol and heated to 90°C for about six hours in a Roth bomb. After cooling to ambient temperature the reaction mixture is evaporated down. The yellowish oily crude product is further reacted without any more purification.
- 10 Mass spectrum (ESI⁺): m/z = 240 [M+Na]⁺

15 Example VII

Methyl (2-hydroxy-4-methoxy-butylamino)-acetate hydrochloride

- 11.94 ml of thionylchloride are added dropwise, within 20 minutes, to a suspension of 5.80 g of (2-hydroxy-4-methoxy-butylamino)-acetic acid in 200 ml methanol while cooling with an ice bath. The reaction mixture is allowed to come up to ambient temperature overnight. For working up, the cloudy solution is evaporated to dryness. The residue is stirred several times with 100 ml aliquots of methanol, which is then distilled off *in vacuo* using the rotary evaporator. The viscous crude product is reacted further without any additional purification.
- 20 Yield: 8.70 g,
- Mass spectrum (ESI⁺): m/z = 192 [M+H]⁺
- 25

Preparation of the final compounds:

30 Example 1

4-[(3-chloro-4-fluoro-phenyl)amino]-6- {[4-((*R*)-2-methoxymethyl-6-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline

950 mg of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(4-{N-[(ethoxycarbonyl)methyl]-N-((*R*)-2-hydroxy-3-methoxy-propyl)-amino}-1-oxo-2-buten-1-yl)amino]-7-

5 cyclopropylmethoxy-quinazoline and 195 µl of methanesulphonic acid in 10 ml acetonitrile are refluxed for about four hours. For working up, the reaction mixture is cooled in a bath of ice water, mixed with 75 ml of ethyl acetate and 25 ml of saturated sodium hydrogen carbonate solution and vigorously stirred for 10 minutes. The organic phase is separated off, washed with saturated sodium hydrogen carbonate solution and
10 saturated sodium chloride solution and dried over magnesium sulphate. The solvent is distilled off *in vacuo*, leaving a brownish foam.

Yield: 610 mg (69 % of theory),

R_f value: 0.55 (silica gel, methylene chloride/methanol = 9:1)

Mass spectrum (ESI⁺): m/z = 570, 572 [M+H]⁺

15

The following compounds are obtained analogously to Example 1:

(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6- {[4-(2-oxo-1,9-dioxa-4-aza-spiro[5.5]undec-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline

20 R_f value: 0.53 (silica gel, methylene chloride/methanol = 15:1)

Mass spectrum (ESI⁻): m/z = 594, 596 [M-H]⁻

(2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6- {[4-((*S*)-2-methoxymethyl-6-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline

R_f value: 0.53 (silica gel, methylene chloride/methanol = 9:1)

25 Mass spectrum (ESI⁻): m/z = 568, 570 [M-H]⁻

Example 2

4-[(3-chloro-4-fluoro-phenyl)amino]-6-({4-[2-(2-methoxy-ethyl)-6-oxo-morpholin-4-yl]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline

- 1.68 ml of oxalyl chloride are pipetted into 1.61 g of bromocrotonic acid in 50 ml methylene chloride, then one more drop of N,N-dimethylformamide is added. The reaction mixture is stirred for about one hour at ambient temperature until the development of gas has ceased, and then evaporated to dryness. The crude bromocrotonic acid chloride is taken up in 20 ml of methylene chloride and while cooling with an ice bath added dropwise, within five minutes, to a solution of 2.50 g of 6-amino-4-[(3-chloro-4-fluorophenyl)amino]-7-cyclopropyl-methoxy-quinazoline and 12.14 ml of diisopropylethylamine in 75 ml of tetrahydrofuran. The reaction mixture is stirred for one hour while cooling with an ice bath, then for another two hours at ambient temperature. A solution of 8.20 g of methyl (2-hydroxy-4-methoxy-butylamino)-acetate hydrochloride in 15 ml N,N-dimethylformamide is added in one go. The reaction mixture is stirred for 24 hours at 75°C. For working up, the reaction mixture is evaporated to dryness and the flask residue is partitioned between 250 ml of ethyl acetate and 200 ml of 5% citric acid solution. The organic phase is washed with saturated sodium chloride solution, dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography through a silica gel column using ethyl acetate as eluant. The cyclised product is obtained as a beige solid.
- Yield: 825 mg (20 % of theory),
 R_f value: 0.38 (silica gel, ethyl acetate)
 Mass spectrum (ESI): m/z = 582, 584 [M-H]⁺

The following compounds may be prepared analogously to the foregoing Examples and other methods known from the literature:

- (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-((S)-2-methoxymethyl-6-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-methoxy-quinazoline
- (2) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-((S)-2-methoxymethyl-6-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-quinazoline

(3) 4-[(*R*)-(1-phenyl-ethyl)amino]-6-({4-[2-(2-methoxy-ethyl)-6-oxo-morpholin-4-yl]-1-oxo-2-buten-1-yl}amino)-quinazoline

(4) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-({4-[3-(2-methoxy-ethyl)-2-oxo-morpholin-4-yl]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline

(5) 4-[(*R*)-(1-phenyl-ethyl)amino]-6-{[4-(2-oxo-1,9-dioxo-4-aza-spiro[5.5]undec-4-yl)-1-oxo-2-buten-1-yl]amino}-7-methoxy-quinazoline

(6) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{{4-(2-oxo-perhydro-cyclopenta[1,4]oxazin-4-yl)-1-oxo-2-buten-1-yl}amino}-7-methoxy-quinazoline

(7) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{{4-(5-oxo-perhydro-2,4-dioxo-7-aza-inden-7-yl)-1-oxo-2-buten-1-yl}amino}-7-methoxy-quinazoline

Example 3

Coated tablets containing 75 mg of active substance

1 tablet core contains:

active substance	75.0 mg
calcium phosphate	93.0 mg
corn starch	35.5 mg
polyvinylpyrrolidone	10.0 mg
hydroxypropylmethylcellulose	15.0 mg
magnesium stearate	<u>1.5 mg</u>
	230.0 mg

Preparation:

The active substance is mixed with calcium phosphate, corn starch, polyvinylpyrrolidone, hydroxypropylmethylcellulose and half the specified amount of magnesium stearate.

5 Weight of core: 230 mg
die: 9 mm, convex

Weight of coated tablet: 245 mg.

10

15 **Composition:**

20

Method of Preparation:

30

-29-

Diameter: 10 mm, biplanar, faceted on both sides and notched on one side.

Example 5

5 Tablets containing 150 mg of active substance

Composition:

1 tablet contains:

	active substance	50.0 mg
10	powdered lactose	89.0 mg
	corn starch	40.0 mg
	colloidal silica	10.0 mg
	polyvinylpyrrolidone	10.0 mg
	magnesium stearate	<u>1.0 mg</u>
15		300.0 mg

Preparation:

20 The active substance mixed with lactose, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. The granules, dried at 45°C, are passed through the same screen again and mixed with the specified amount of magnesium stearate. Tablets are pressed from the mixture.

Weight of tablet: 300 mg

die: 10 mm, flat

25

Example 6

Hard gelatine capsules containing 150 mg of active substance

30 1 capsule contains:

active substance 50.0 mg

corn starch (dried) approx.	80.0 mg
lactose (powdered) approx.	87.0 mg
magnesium stearate	<u>3.0 mg</u>
approx.	420.0 mg

5

Preparation:

The active substance is mixed with the excipients, passed through a screen with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The finished mixture is packed into size 1 hard gelatine capsules.

Capsule filling: approx. 320 mg

Capsule shell: size 1 hard gelatine capsule.

15 Example 7

Suppositories containing 150 mg of active substance

1 suppository contains:

20	active substance	150.0 mg
	polyethyleneglycol 1500	550.0 mg
	polyethyleneglycol 6000	460.0 mg
	polyoxyethylene sorbitan monostearate	<u>840.0 mg</u>
		2,000.0 mg

25

Preparation:

After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled moulds.

30

Example 8

Suspension containing 50 mg of active substance

100 ml of suspension contain:

5	active substance	1.00 g
	carboxymethylcellulose-Na-salt	0.10 g
	methyl p-hydroxybenzoate	0.05 g
	propyl p-hydroxybenzoate	0.01 g
	glucose	10.00 g
10	glycerol	5.00 g
	70% sorbitol solutio	20.00 g
	flavouring	0.30 g
	dist. water	ad 100 ml

15 Preparation:

The distilled water is heated to 70°C. The methyl and propyl p-hydroxybenzoates together with the glycerol and carboxy-methylcellulose sodium salt are dissolved therein with stirring. The solution is cooled to ambient temperature and the active substance is added and homogeneously dispersed therein with stirring. After the sugar, the sorbitol solution and the flavouring have been added and dissolved, the suspension is evacuated with stirring to eliminate air.

5 ml of suspension contain 50 mg of active substance.

25 Example 9

Ampoules containing 10 mg active substance

Composition:

30	active substance	10.0 mg
	0.01 N hydrochloric acid q.s.	

double-distilled water ad 2.0 ml

Preparation:

- 5 The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with common salt, filtered sterile and transferred into 2 ml ampoules.

Example 10

- 10 Ampoules containing 50 mg of active substance

Composition:

- | | | |
|----|-------------------------------|---------|
| | active substance | 50.0 mg |
| | 0.01 N hydrochloric acid q.s. | |
| 15 | double-distilled water ad | 10.0 ml |

Preparation:

- 20 The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with common salt, filtered sterile and transferred into 10 ml ampoules.

Example 11

- 25 Capsules for powder inhalation containing 5 mg of active substance

1 capsule contains:

- | | | |
|----|------------------------|----------------|
| | active substance | 5.0 mg |
| 30 | lactose for inhalation | <u>15.0 mg</u> |
| | | 20.0 mg |

Preparation:

The active substance is mixed with lactose for inhalation. The mixture is packed into capsules in a capsule-making machine (weight of the empty capsule approx. 50 mg).

weight of capsule: 70.0 mg

size of capsule = 3

10 Example 12

Solution for inhalation for hand-held nebulisers containing 2.5 mg active substance

1 spray contains:

15

active substance 2.500 mg

benzalkonium chloride 0.001 mg

1N hydrochloric acid q.s.

ethanol/water (50/50) ad 15.000 mg

20

Preparation:

The active substance and benzalkonium chloride are dissolved in ethanol/water (50/50).

The pH of the solution is adjusted with 1N hydrochloric acid. The resulting solution is

25 filtered and transferred into suitable containers for use in hand-held nebulisers (cartridges).

Contents of the container: 4.5 g